| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Pathology, 2 Medical Oncology, 3 Urology, and 4 Biostatistics, University of Michigan School of Medicine, Ann Arbor, Michigan; 5 Department of Pathology, Brigham and Womens Hospital, Boston, Massachusetts; 6 Department of Pathology, Dana Farber Cancer Institute, Boston, Massachusetts; and 7 Department of Pathology, Harvard Medical School, Boston, Massachusetts
Understanding the biology of prostate cancer metastasis has been limited by the lack of tissue for study. We studied the clinical data, distribution of prostate cancer involvement, morphology, immunophenotypes, and gene expression from 30 rapid autopsies of men who died of hormone-refractory prostate cancer. A tissue microarray was constructed and quantitatively evaluated for expression of prostate-specific antigen, androgen receptor, chromogranin, synaptophysin, MIB-1, and
-methylacylCoA-racemase markers. Hierarchical clustering of 16 rapid autopsy tumor samples was performed to evaluate the cDNA expression pattern associated with the morphology. Comparisons were made between patients as well as within the same patient. Metastatic hormone-refractory prostate cancer has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that "metastatic disease" is a group of diseases even within the same patient. An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease.
This article has been cited by other articles:
![]() |
M. P. Steinkamp, O. A. O'Mahony, M. Brogley, H. Rehman, E. W. LaPensee, S. Dhanasekaran, M. D. Hofer, R. Kuefer, A. Chinnaiyan, M. A. Rubin, et al. Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy Cancer Res., May 15, 2009; 69(10): 4434 - 4442. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Vander Griend, L. Antony, S. L. Dalrymple, Y. Xu, S. B. Christensen, S. R. Denmeade, and J. T. Isaacs Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells Mol. Cancer Ther., May 1, 2009; 8(5): 1340 - 1349. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, P. Nangia-Makker, L. Tait, V. Balan, V. Hogan, K. J. Pienta, and A. Raz Regulation of Prostate Cancer Progression by Galectin-3 Am. J. Pathol., April 1, 2009; 174(4): 1515 - 1523. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Bedolla, Y. Wang, A. Asuncion, K. Chamie, S. Siddiqui, M. M. Mudryj, T. J. Prihoda, J. Siddiqui, A. M. Chinnaiyan, R. Mehra, et al. Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases Clin. Cancer Res., February 1, 2009; 15(3): 788 - 796. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tsuji, S. Ibaragi, K. Shima, M. G. Hu, M. Katsurano, A. Sasaki, and G.-f. Hu Epithelial-Mesenchymal Transition Induced by Growth Suppressor p12CDK2-AP1 Promotes Tumor Cell Local Invasion but Suppresses Distant Colony Growth Cancer Res., December 15, 2008; 68(24): 10377 - 10386. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. A. O'Mahony, M. P. Steinkamp, M. A. Albertelli, M. Brogley, H. Rehman, and D. M. Robins Profiling Human Androgen Receptor Mutations Reveals Treatment Effects in a Mouse Model of Prostate Cancer Mol. Cancer Res., November 1, 2008; 6(11): 1691 - 1701. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Martinez, R. J. Jasavala, I. Hinkson, L. D. Fitzgerald, J. S. Trimmer, H.-J. Kung, and M. E. Wright RNA Editing of Androgen Receptor Gene Transcripts in Prostate Cancer Cells J. Biol. Chem., October 31, 2008; 283(44): 29938 - 29949. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-M. Lin, C.-H. Tsai, Y.-C. Yang, W.-C. Tu, L.-R. Chen, Y.-S. Liang, S.-Y. Wang, L.-F. Shyur, S.-C. Chien, T.-L. Cha, et al. A Novel Diterpene Suppresses CWR22Rv1 Tumor Growth In vivo through Antiproliferation and Proapoptosis Cancer Res., August 15, 2008; 68(16): 6634 - 6642. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chu, C.-J. Cheng, X. Ye, Y.-C. Lee, A. J. Zurita, D.-T. Chen, L.-Y. Yu-Lee, S. Zhang, E. T. Yeh, M. C-T. Hu, et al. Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone Mol. Cancer Res., August 1, 2008; 6(8): 1259 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Lin, Y.-C. Lee, M. B. Choueiri, S. Wen, P. Mathew, X. Ye, K.-A. Do, N. M. Navone, J. Kim, S.-M. Tu, et al. Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer Clin. Cancer Res., June 15, 2008; 14(12): 3729 - 3736. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Montgomery, E. A. Mostaghel, R. Vessella, D. L. Hess, T. F. Kalhorn, C. S. Higano, L. D. True, and P. S. Nelson Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth Cancer Res., June 1, 2008; 68(11): 4447 - 4454. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mehra, S. A. Tomlins, J. Yu, X. Cao, L. Wang, A. Menon, M. A. Rubin, K. J. Pienta, R. B. Shah, and A. M. Chinnaiyan Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer Cancer Res., May 15, 2008; 68(10): 3584 - 3590. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Frigo and D. P. McDonnell Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation Mol. Cancer Ther., March 1, 2008; 7(3): 659 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Najy, K. C. Day, and M. L. Day ADAM15 Supports Prostate Cancer Metastasis by Modulating Tumor Cell-Endothelial Cell Interaction Cancer Res., February 15, 2008; 68(4): 1092 - 1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Lin, D. Chang, A. Chiang, and S.-Y. Ying Androgen receptor regulates CD168 expression and signaling in prostate cancer Carcinogenesis, February 1, 2008; 29(2): 282 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Sterbis, C. Gao, B. Furusato, Y. Chen, S. Shaheduzzaman, L. Ravindranath, D. J. Osborn, I. L. Rosner, A. Dobi, D. G. McLeod, et al. Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival Clin. Cancer Res., February 1, 2008; 14(3): 758 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Albertelli, O. A. O'Mahony, M. Brogley, J. Tosoian, M. Steinkamp, S. Daignault, K. Wojno, and D. M. Robins Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice Hum. Mol. Genet., January 1, 2008; 17(1): 98 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Setlur, T. E. Royce, A. Sboner, J.-M. Mosquera, F. Demichelis, M. D. Hofer, K. D. Mertz, M. Gerstein, and M. A. Rubin Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer Cancer Res., November 1, 2007; 67(21): 10296 - 10303. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mehra, B. Han, S. A. Tomlins, L. Wang, A. Menon, M. J. Wasco, R. Shen, J. E. Montie, A. M. Chinnaiyan, and R. B. Shah Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases Cancer Res., September 1, 2007; 67(17): 7991 - 7995. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Shen and C. Abate-Shen Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer Cancer Res., July 15, 2007; 67(14): 6535 - 6538. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chen, X.-C. Ye, K. Chu, N. M. Navone, E. H. Sage, L.-Y. Yu-Lee, C. J. Logothetis, and S.-H. Lin A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells Cancer Res., July 15, 2007; 67(14): 6544 - 6548. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Loberg, D. A. Bradley, S. A. Tomlins, A. M. Chinnaiyan, and K. J. Pienta The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy CA Cancer J Clin, July 1, 2007; 57(4): 225 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Isayeva, D. Chanda, L. Kallman, I.-E. A. Eltoum, and S. Ponnazhagan Effects of Sustained Antiangiogenic Therapy in Multistage Prostate Cancer in TRAMP Model Cancer Res., June 15, 2007; 67(12): 5789 - 5797. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tamura, M. Furihata, T. Tsunoda, S. Ashida, R. Takata, W. Obara, H. Yoshioka, Y. Daigo, Y. Nasu, H. Kumon, et al. Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles Cancer Res., June 1, 2007; 67(11): 5117 - 5125. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption Cancer Res., April 15, 2007; 67(8): 3646 - 3653. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, et al. Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2023 - 2029. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. I. Scher, M. Warren, and G. Heller The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1488 - 1492. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Lin, D. Chang, and S.-Y. Ying Hyaluronan stimulates transformation of androgen-independent prostate cancer Carcinogenesis, February 1, 2007; 28(2): 310 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Davis, K. J. Wojno, S. Daignault, M. D. Hofer, R. Kuefer, M. A. Rubin, and M. L. Day Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer Cancer Res., December 15, 2006; 66(24): 11897 - 11906. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pootrakul, R. H. Datar, S.-R. Shi, J. Cai, D. Hawes, S. G. Groshen, A. S. Lee, and R. J. Cote Expression of Stress Response Protein Grp78 Is Associated with the Development of Castration-Resistant Prostate Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 5987 - 5993. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Vessella and E. Corey Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. V. Litvinov, D. J. Vander Griend, L. Antony, S. Dalrymple, A. M. De Marzo, C. G. Drake, and J. T. Isaacs Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells PNAS, October 10, 2006; 103(41): 15085 - 15090. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Dehm and D. J. Tindall Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells J. Biol. Chem., September 22, 2006; 281(38): 27882 - 27893. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Axelrod, D. E. Axelrod, and K. J. Pienta From the Cover: Evolution of cooperation among tumor cells PNAS, September 5, 2006; 103(36): 13474 - 13479. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Perner, F. Demichelis, R. Beroukhim, F. H. Schmidt, J.-M. Mosquera, S. Setlur, J. Tchinda, S. A. Tomlins, M. D. Hofer, K. G. Pienta, et al. TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Res., September 1, 2006; 66(17): 8337 - 8341. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Park, Y.-J. Kim, A. C. Gao, J. L. Mohler, S. A. Onate, A. A. Hidalgo, C. Ip, E.-M. Park, S. Y. Yoon, and Y.-M. Park Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res., May 15, 2006; 66(10): 5121 - 5129. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Gomez, A. de las Pozas, and C. Perez-Stable Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1216 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Varghese, S. D. Rabkin, P. G. Nielsen, W. Wang, and R. L. Martuza Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin. Cancer Res., May 1, 2006; 12(9): 2919 - 2927. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Han, H. Xie, Q. Chen, and J.-T. Zhang Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}. Mol. Cancer Ther., April 1, 2006; 5(4): 903 - 912. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wallner, J. Dai, J. Escara-Wilke, J. Zhang, Z. Yao, Y. Lu, M. Trikha, J. A. Nemeth, M. H. Zaki, and E. T. Keller Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice. Cancer Res., March 15, 2006; 66(6): 3087 - 3095. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Pienta and D. Bradley Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671. [Full Text] [PDF] |
||||
![]() |
M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res., March 1, 2006; 66(5): 2815 - 2825. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kitagawa, J. Dai, J. Zhang, J. M. Keller, J. Nor, Z. Yao, and E. T. Keller Vascular Endothelial Growth Factor Contributes to Prostate Cancer-Mediated Osteoblastic Activity Cancer Res., December 1, 2005; 65(23): 10921 - 10929. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Ross, S. Halabi, S.-S. Ou, B. R. Rajeshkumar, B. A. Woda, N. J. Vogelzang, E. J. Small, M.-E. Taplin, and P. W. Kantoff Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer--A Cancer and Leukemia Group B Study Clin. Cancer Res., November 15, 2005; 11(22): 8109 - 8113. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. I. Scher and C. L. Sawyers Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Pulukuri, C. S. Gondi, S. S. Lakka, A. Jutla, N. Estes, M. Gujrati, and J. S. Rao RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo J. Biol. Chem., October 28, 2005; 280(43): 36529 - 36540. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism Cancer Res., September 15, 2005; 65(18): 8274 - 8285. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Pienta and D. C. Smith Advances in Prostate Cancer Chemotherapy: A New Era Begins CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Dimitroff, L. Descheny, N. Trujillo, R. Kim, V. Nguyen, W. Huang, K. J. Pienta, J. L. Kutok, and M. A. Rubin Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells Cancer Res., July 1, 2005; 65(13): 5750 - 5760. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer {alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |